Autonomix Medical, Inc. Common Stock (AMIX) 10-Q 13 Aug 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2024	Aug. 02, 2024
Document Information [Line Items]
Entity Central Index Key	0001617867
Entity Registrant Name	Autonomix Medical, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-41940
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-1607810
Entity Address, Address Line One	21 Waterway Avenue, Suite 300
Entity Address, City or Town	The Woodlands
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77380
City Area Code	713
Local Phone Number	588-6150
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	AMIX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		23,036,933

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024
Current assets:
Cash and cash equivalents	$ 6,751	$ 8,608
Other current assets	325	783
Total current assets	7,076	9,391
Long term assets:
Fixed assets, net	19	16
Total long term assets	19	16
Total Assets	7,095	9,407
Current liabilities:
Accounts payable	287	492
Accrued expenses	476	285
Total current liabilities	763	777
Long term liabilities:
Long term debt - convertible notes, net of unamortized debt discount	1,043	1,002
Total long term liabilities	1,043	1,002
Total Liabilities	1,806	1,779
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively	0	0
Common stock, $0.001 par value, 500,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, 19,242,081 and 18,846,094 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively	19	19
Additional paid-in capital	46,938	46,578
Accumulated deficit	(41,668)	(38,969)
Total Stockholders' Equity	5,289	7,628
Total Liabilities and Stockholders' Equity	$ 7,095	$ 9,407

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2024	Mar. 31, 2024
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	500,000,000	500,000,000
Common stock, issued (in shares)	19,242,081	18,846,094
Common stock, outstanding (in shares)	19,242,081	18,846,094

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating expenses:
General and administrative expense	$ 1,799	$ 503
Research and development expense	954	368
Total operating expenses	2,753	871
Loss from operations	(2,753)	(871)
Other (expense) income:
Interest expense	(41)	0
Interest income	95	6
Total other income	54	6
Loss before income taxes	(2,699)	(865)
Income taxes	0	0
Net loss	$ (2,699)	$ (865)
Loss per share - basic and diluted (in dollars per share)	$ (0.14)	$ (0.07)
Weighted average shares outstanding - basic and diluted (in shares)	18,902,248	12,884,604

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2023	0	12,337
Balance at Mar. 31, 2023	$ 0	$ 12	$ 24,175	$ (23,543)	$ 644
Net Loss	$ 0	$ 0	0	(865)	(865)
Issuance of common stock (in shares)	0	1,420
Issuance of common stock	$ 0	$ 2	2,838	0	2,840
Balance (in shares) at Jun. 30, 2023	0	13,757
Balance at Jun. 30, 2023	$ 0	$ 14	27,013	(24,408)	2,619
Balance (in shares) at Mar. 31, 2024	0	18,846
Balance at Mar. 31, 2024	$ 0	$ 19	46,578	(38,969)	7,628
Net Loss	$ 0	$ 0	0	(2,699)	(2,699)
Balance (in shares) at Jun. 30, 2024	0	19,242
Balance at Jun. 30, 2024	$ 0	$ 19	46,938	(41,668)	5,289
Stock-based compensation	$ 0	$ 0	360	0	360
Refund of common stock from IPO (in shares)	0	(1)
Issuance of common stock - warrants exercised (in shares)	0	397
Issuance of common stock - warrants exercised	$ 0	$ 0	$ 0	$ 0	$ 0

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities:
Net Loss	$ (2,699)	$ (865)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	360	0
Depreciation and amortization expense	43	0
Changes in operating assets - decrease/(increase):
Other current assets	458	(25)
Changes in operating liabilities - (decrease)/increase:
Accounts payable	(205)	209
Accrued expenses	191	20
Net cash used in operating activities	(1,852)	(661)
Cash Flows from Investing Activities:
Purchase of property and equipment	(5)	0
Net cash used in investing activities	(5)	0
Cash Flows from Financing Activities:
Issuance of common stock	0	2,840
Payment of offering costs	0	(105)
Net cash provided by financing activities	0	2,735
Net change in cash and cash equivalents	(1,857)	2,074
Cash and cash equivalents, at beginning of period	8,608	865
Cash and cash equivalents, at end of period	6,751	2,939
Non-cash financing activities:
Cashless exercise of warrants	$ 4	$ 0

Note 1 - Description of the Bus

Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1 Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies Description of the Business Autonomix Medical, Inc. (“we,” “our,” the “Company”) is a medical device company organized as a Delaware corporation on June 10, 2014. Liquidity and Going Concern The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception. For the three June 30, 2024 2023 no three June 30, 2024 2023 June 30, 2024 not The Company estimates its current cash resources are sufficient to fund its operations into but not second 2025. no These factors raise substantial doubt about the Company's ability to continue as a going concern within one not Basis of Presentation The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not March 31 st March 31, 2024 10 May 31, 2024. not may March 31, 2024 not Use of Estimates in Financial Statement Presentation The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but not Cash and Cash Equivalents The Company considers all highly liquid accounts with original maturities of three may $250,000. not not Offering Costs Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company’s initial public offering ("IPO"). These costs, together with the selling agent fees, were reclassified to additional paid-in capital upon completion of the Company’s IPO on January 26, 2024. During the three June 30, 2024 2023 $0 Property and Equipment Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally three Convertible Notes The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company’s debt is carried on the condensed balance sheets on a historical cost basis net of unamortized discounts and premiums because the Company has not If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above. In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with no Fair Value of Financial Instruments Fair value is defined as the exchange price that would be receiv three Level 1 Level 2 Level 3 Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used. The Company did not three June 30, 2024 March 31, 2024 not 3 June 30, 2024 March 31, 2024 As of June 30, 2024, was 2 The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments. Related Parties The Company follows Accounting Standards Codification ("ASC") 850, Related Party Disclosures 5 Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not not June 30, 2024 March 31, 2024 The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740 10 not June 30, 2024 March 31, 2024 The Company does not 2025 March 31, 2025) three June 30, 2024 2025 not” not The Company recorded no three June 30, 2024 2023 three June 30, 2024 2023 no Stock-based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative expenses and forfeitures are recognized as they are incurred. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC 480, 480” 815, 815” 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company’s outstanding warrants are non-participating securities as they are not no However, the warrants described in Note 5 not no For the three June 30, 2024 2023 not June 30, 2024 2023 Equity based warrants to purchase common shares 5,344,569 6,569,929 Convertible Notes - common shares 665,000 - Convertible Notes - equity-based warrants to purchase common shares 500,000 - Stock options granted under Company's incentive plan 4,329,579 933,600 Total potentially dilutive securities 10,839,148 7,503,529 Research and Development Costs Research and development costs are expensed as incurred. Advertising It is our policy to expense advertising costs as incurred. Advertising expenses are included within general and administrative expenses within the statement of operations. For the three June 30, 2024 2023, Fair Value of Common Stock Prior to establishing a public market for the Company’s common stock, the estimated fair value of the Company’s common stock was determined by the Company’s board of directors as of the date of each option grant, with input from management, considering the Company’s most recently available third third may JOBS Act Accounting Election The Company qualifies as an emerging growth company (“EGC”), as defined in the Jumpstart Our Business Startups Act of 2012 not may Segments The Company currently operates in one one Recent Accounting Pronouncements In December 2023, 2023 09, 740 December 15, 2024, not The Company does not not Correction of an Immaterial Error in the Prior Period Financial Statements During the fourth 2024 March 31, 2024), 730 SEC Staff Accounting Bulletin No. 99 Materiality ASC Topic 250, not no 2023 not A summary of immaterial corrections reflecting the prior period impact to the Company’s Statement of Operations, for the quarter ended June 30, 2023 As Revised June 30, 2023 Correction June 30, 2023 General and administrative expense $ 523 $ (20 ) $ 503 Research and development expense 348 20 368 Net Loss $ 871 $ - $ 871

Note 2 - Convertible Notes Paya

Note 2 - Convertible Notes Payable	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 2 Convertible Notes Payable On September 9, 2023, December 31, 2025. five The Bridge Financing Warrants can be exercised from the date of Notes issuance through the five four not As of June 30, 2024 January 26, 2024, not The table below summarizes the Company’s outstanding convertible notes payable as of June 30, 2024 Principal Amount Amortized Debt Discount Net Carrying Amount Zero-coupon convertible notes payable due on December 31, 2025 $ 1,330 $ 287 $ 1,043 Warrants The Company issued the Notes with detachable warrants for the purchase of shares of the Company’s common stock. The Company utilized a Monte Carlo simulation model to determine the fair value of each Bridge Offering Warrant. The key inputs to the Monte Carlo simulation used to determine the fair value of each warrant include, the Company’s stock price fair value which was determined through a back solve calculation such that the stock price results in the average total value of the Notes and the Bridge Offering Warrants being equal to the cash proceeds received, volatility based on a selection of publicly held peer companies of 101.88%, expected term of 5 years, risk free rate of 4.40%, discount rate of 20.00% and a discount for lack of marketability of 15.77%. During the three June 30, 2024 The following table presents a summary of activity for the warrants issued in connection with the Company’s Notes: Weighted-Average Exercise Price Remaining Life Aggregate Warrants Per Share (In Years) Intrinsic Value* Outstanding and exercisable, March 31, 2024 500,000 $ 1.00 4.48 $ 1,010,000 Granted - - - - Exercised - - - - Forfeited/Cancelled - - - - Expired - - - - Outstanding, June 30, 2024 500,000 $ 1.00 4.23 $ - Exercisable, June 30, 2024 500,000 $ 1.00 4.23 $ - *Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. No June 30, 2024

Note 3 - Equity

Note 3 - Equity	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 3 Equity On January 26, 2024, May 13, 2024 not On November 29, 2023, $.001 $.001 Restricted Stock On February 15, 2024, 12 Quarter ended June 30, 2024 2023 Recognized in general and administrative expense $ 33,250 $ — Total $ 33,250 $ — For the quarter ended June 30, 2024, July 2024 February 2025. A summary of activity regarding Restricted Stock issued is as follows: Grant Date Number of Shares Fair Value Per Share Unvested, March 31, 2024 32,083 $ 3.80 Granted — $ — Vested (8,750 ) $ 3.80 Unvested, June 30, 2024 23,333 $ 3.80 Common Stock On April 6, 2023, three June 30, 2023, not On September 9, 2023, 3 Convertible Notes Payable Stock Plan and Stock Options In June 2023, 2023 In August 2023, 1st April 1, 2024 April 1, 2033 five March 31st may no April 1, 2024, The following table summarizes the stock option activity for the three June 30, 2024 Weighted-Average Weighted-Average Exercise Price Remaining Life Aggregate Options Per Share (In Years) Intrinsic Value* Outstanding and exercisable, March 31, 2024 2,003,600 $ 2.33 9.35 $ 1,680,672 Granted 2,325,979 1.38 - - Exercised - - - - Forfeited/Cancelled - - - - Expired - - - - Outstanding, June 30, 2024 4,329,579 $ 1.82 9.57 $ - Exercisable, June 30, 2024* 321,317 $ 2.00 8.69 $ - *Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock. No June 30, 2024 During the three June 30, 2024 four 1 2 3 two 4 All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at June 30, 2024 three June 30, 2024 three June 30, 2023 Equity-Based Stock Warrants The Company will periodically grant warrants to investors in connection with equity financing or to third three June 30, 2024 Weighted-Average Weighted-Average Exercise Price Remaining Life Aggregate Warrants Per Share (In Years) Intrinsic Value* Outstanding, March 31, 2024 5,744,569 $ 0.08 4.80 $ 17,072,147 Granted - - - - Exercised** (397,037 ) 0.01 - - Forfeited/Cancelled (2,963 ) 0.01 - - Expired - - - - Outstanding, June 30, 2024 5,344,569 $ 0.09 4.54 $ 5,009,401 Exercisable, June 30, 2024 5,341,236 $ 0.09 4.54 $ 5,009,401 * Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. 5,257,929 outstanding and exercisable warrants were in-the-money as of June 30, 2024 ** All exercised warrants utilized the “cashless exercise” option. The unrecognized compensation expense at June 30, 2024 three June 30, 2024 no three June 30, 2023

Note 4 - Commitments and Contin

Note 4 - Commitments and Contingencies	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 4 Commitments and Contingencies Legal Proceedings From time to time, we may not Employment Agreements We have agreements with key employees to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In addition, the Company has adopted a severance policy for certain key members of executive management to provide certain benefits, including salary and other wage-related benefits, in the event of termination. In total, these benefits would amount to a range of $1.1 million to $1.6 June 30, 2024 Brad Hauser - Chief Executive Officer On June 17, 2024, three may ten four four 2023 5635 4 March 31, 2025, If Mr. Hauser’s employment is terminated at our election without “cause,” or by Mr. Hauser for “good reason,” Mr. Hauser shall be entitled to receive severance payments equal to twelve three twelve 4999 Lori Bisson Vice Chair (former Chief Executive Officer) On June 17, 2024, two March 31, 2024 not March 31, 2025, June 30, 2023.

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 5 Related Party Transactions The Company utilizes a consulting firm that is owned by the Company’s former Chief Financial Officer to provide accounting and financial reporting services and pays certain expenses on behalf of the Company. During the three June 30, 2024 2023 June 30, 2024 March 31, 2024 As of June 30, 2024 On December 21, 2021, 90 may On July 7, 2023, one may five six twelve On January 29, 2024, . may five six twelve 20

Note 6 - Subsequent Events

Note 6 - Subsequent Events	3 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 6 Subsequent Events On July 10, 2024, 6 6 not In July 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. Other Information During the period covered by this Quarterly Report, none 10b5 1 10b5 1 408 1934,
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Substantial Doubt About Going Concern Policy [Policy Text Block]	Liquidity and Going Concern The Company's financial statements are prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company is an early-stage company that is subject to all the risks associated with early-stage and emerging growth companies and has incurred losses since inception. For the three June 30, 2024 2023 no three June 30, 2024 2023 June 30, 2024 not The Company estimates its current cash resources are sufficient to fund its operations into but not second 2025. no These factors raise substantial doubt about the Company's ability to continue as a going concern within one not
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not March 31 st March 31, 2024 10 May 31, 2024. not may March 31, 2024 not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates in Financial Statement Presentation The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid accounts with original maturities of three may $250,000. not not
Offering Costs, Policy [Policy Text Block]	Offering Costs Offering costs consist of professional costs incurred through the balance sheet date that are direct and incremental related to the Company’s initial public offering ("IPO"). These costs, together with the selling agent fees, were reclassified to additional paid-in capital upon completion of the Company’s IPO on January 26, 2024. During the three June 30, 2024 2023 $0
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment (comprised of computer and IT equipment) are stated at historical cost and depreciated on a straight-line basis over their estimated useful lives, generally three
Debt, Policy [Policy Text Block]	Convertible Notes The Company evaluates embedded redemption, conversion and other features within its debt to determine whether any embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value, with changes in fair value recorded in the condensed statements of operations. The Company’s debt is carried on the condensed balance sheets on a historical cost basis net of unamortized discounts and premiums because the Company has not If the Company incurs costs associated with its convertible notes, in advance of the receipt of proceeds, the Company will record a deferred asset. Upon receipt of proceeds the Company will reclassify the deferred asset as a direct deduction from the carrying amount, as described above. In addition, since the instruments included a substantive conversion feature as of time of issuance, the issuance of equity securities to settle the outstanding notes with the conversion were accounted for as a contractual conversion with no
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Fair value is defined as the exchange price that would be receiv three Level 1 Level 2 Level 3 Financial assets and financial liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. While the Company believes that its valuation methods are appropriate, the Company recognizes that the use of different methodologies or assumptions to determine the fair value could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values are the probability weighting of the different settlement outcomes used. The Company did not three June 30, 2024 March 31, 2024 not 3 June 30, 2024 March 31, 2024 As of June 30, 2024, was 2 The carrying value of short-term instruments, including cash, accounts payable and accrued expenses, approximate fair value due to the relatively short period to maturity for these instruments.
Related Party Transactions Policy [Policy Text Block]	Related Parties The Company follows Accounting Standards Codification ("ASC") 850, Related Party Disclosures 5
Income Tax, Policy [Policy Text Block]	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not not June 30, 2024 March 31, 2024 The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740 10 not June 30, 2024 March 31, 2024 The Company does not 2025 March 31, 2025) three June 30, 2024 2025 not” not The Company recorded no three June 30, 2024 2023 three June 30, 2024 2023 no
Share-Based Payment Arrangement [Policy Text Block]	Stock-based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. For awards with a performance condition, compensation expense is recognized over the requisite service period if it is probable that the performance condition will be satisfied. For awards to non-employees, the Company recognizes compensation expense in the same manner as if the Company had paid cash for the goods or services. The Company estimates the fair value of options and equity classified warrants granted using an options pricing model. Expense is recognized within general and administrative expenses and forfeitures are recognized as they are incurred.
Warrants, Policy [Policy Text Block]	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC 480, 480” 815, 815” 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not
Earnings Per Share, Policy [Policy Text Block]	Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Generally, the Company’s outstanding warrants are non-participating securities as they are not no However, the warrants described in Note 5 not no For the three June 30, 2024 2023 not June 30, 2024 2023 Equity based warrants to purchase common shares 5,344,569 6,569,929 Convertible Notes - common shares 665,000 - Convertible Notes - equity-based warrants to purchase common shares 500,000 - Stock options granted under Company's incentive plan 4,329,579 933,600 Total potentially dilutive securities 10,839,148 7,503,529
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are expensed as incurred.
Advertising Cost [Policy Text Block]	Advertising It is our policy to expense advertising costs as incurred. Advertising expenses are included within general and administrative expenses within the statement of operations. For the three June 30, 2024 2023,
Stockholders' Equity, Policy [Policy Text Block]	Fair Value of Common Stock Prior to establishing a public market for the Company’s common stock, the estimated fair value of the Company’s common stock was determined by the Company’s board of directors as of the date of each option grant, with input from management, considering the Company’s most recently available third third may
Jumpstart Our Business Startups (JOBS) Act Accounting Election Policy [Policy Text Block]	JOBS Act Accounting Election The Company qualifies as an emerging growth company (“EGC”), as defined in the Jumpstart Our Business Startups Act of 2012 not may
Segment Reporting, Policy [Policy Text Block]	Segments The Company currently operates in one one
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In December 2023, 2023 09, 740 December 15, 2024, not The Company does not not
Reclassification, Comparability Adjustment [Policy Text Block]	Correction of an Immaterial Error in the Prior Period Financial Statements During the fourth 2024 March 31, 2024), 730 SEC Staff Accounting Bulletin No. 99 Materiality ASC Topic 250, not no 2023 not A summary of immaterial corrections reflecting the prior period impact to the Company’s Statement of Operations, for the quarter ended June 30, 2023 As Revised June 30, 2023 Correction June 30, 2023 General and administrative expense $ 523 $ (20 ) $ 503 Research and development expense 348 20 368 Net Loss $ 871 $ - $ 871

Note 1 - Description of the B_2

Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2024 2023 Equity based warrants to purchase common shares 5,344,569 6,569,929 Convertible Notes - common shares 665,000 - Convertible Notes - equity-based warrants to purchase common shares 500,000 - Stock options granted under Company's incentive plan 4,329,579 933,600 Total potentially dilutive securities 10,839,148 7,503,529
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	As Revised June 30, 2023 Correction June 30, 2023 General and administrative expense $ 523 $ (20 ) $ 503 Research and development expense 348 20 368 Net Loss $ 871 $ - $ 871

Note 2 - Convertible Notes Pa_2

Note 2 - Convertible Notes Payable (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Convertible Debt [Table Text Block]	Principal Amount Amortized Debt Discount Net Carrying Amount Zero-coupon convertible notes payable due on December 31, 2025 $ 1,330 $ 287 $ 1,043
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted-Average Exercise Price Remaining Life Aggregate Warrants Per Share (In Years) Intrinsic Value* Outstanding and exercisable, March 31, 2024 500,000 $ 1.00 4.48 $ 1,010,000 Granted - - - - Exercised - - - - Forfeited/Cancelled - - - - Expired - - - - Outstanding, June 30, 2024 500,000 $ 1.00 4.23 $ - Exercisable, June 30, 2024 500,000 $ 1.00 4.23 $ -

Note 3 - Equity (Tables)

Note 3 - Equity (Tables)	3 Months Ended
	Jun. 30, 2024
Notes Tables
Restricted Stock Expenses, General and Administrative [Table Text Block]	Quarter ended June 30, 2024 2023 Recognized in general and administrative expense $ 33,250 $ — Total $ 33,250 $ —
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Grant Date Number of Shares Fair Value Per Share Unvested, March 31, 2024 32,083 $ 3.80 Granted — $ — Vested (8,750 ) $ 3.80 Unvested, June 30, 2024 23,333 $ 3.80
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted-Average Weighted-Average Exercise Price Remaining Life Aggregate Options Per Share (In Years) Intrinsic Value* Outstanding and exercisable, March 31, 2024 2,003,600 $ 2.33 9.35 $ 1,680,672 Granted 2,325,979 1.38 - - Exercised - - - - Forfeited/Cancelled - - - - Expired - - - - Outstanding, June 30, 2024 4,329,579 $ 1.82 9.57 $ - Exercisable, June 30, 2024* 321,317 $ 2.00 8.69 $ -
Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]	Weighted-Average Weighted-Average Exercise Price Remaining Life Aggregate Warrants Per Share (In Years) Intrinsic Value* Outstanding, March 31, 2024 5,744,569 $ 0.08 4.80 $ 17,072,147 Granted - - - - Exercised** (397,037 ) 0.01 - - Forfeited/Cancelled (2,963 ) 0.01 - - Expired - - - - Outstanding, June 30, 2024 5,344,569 $ 0.09 4.54 $ 5,009,401 Exercisable, June 30, 2024 5,341,236 $ 0.09 4.54 $ 5,009,401

Note 1 - Description of the B_3

Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2024 USD ($)
Net Income (Loss) Attributable to Parent	$ (2,699)	$ (865)
Net Cash Provided by (Used in) Operating Activities	(1,852)	(661)
Revenues	0	0
Retained Earnings (Accumulated Deficit)	(41,668)		$ (38,969)
Working Capital (Deficit)	6,300
Cash and Cash Equivalents, at Carrying Value	6,751		$ 8,608
Payments for Initial Public Offering Issuance Costs	$ 0	100
Property, Plant and Equipment, Useful Life (Year)	3 years
Long-Term Debt, Fair Value	$ 1,000
Liability for Uncertainty in Income Taxes, Current	0	0
Income Tax Expense (Benefit)	0	0
Advertising Expense	$ 100	$ 100
Number of Reportable Segments	1
Number of Operating Segments		1

Note 1 - Description of the B_4

Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities (Details) - shares	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive securities (in shares)	10,839,148	7,503,529
Warrant [Member]
Antidilutive securities (in shares)	5,344,569	6,569,929
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	665,000	0
Convertible Notes to Warrant [Member]
Antidilutive securities (in shares)	500,000	0
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	4,329,579	933,600

Note 1 - Description of the B_5

Note 1 - Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Prior Period Corrections (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
General and administrative expense	$ 1,799	$ 503
Research and development expense	954	368
Net Loss	$ (2,699)	(865)
Previously Reported [Member]
General and administrative expense		523
Research and development expense		348
Net Loss		871
Revision of Prior Period, Adjustment [Member]
General and administrative expense		(20)
Research and development expense		20
Net Loss		0
As Revised [Member]
General and administrative expense		503
Research and development expense		368
Net Loss		$ 871

Note 2 - Convertible Notes Pa_3

Note 2 - Convertible Notes Payable (Details Textual) $ / shares in Units, $ in Millions			3 Months Ended	10 Months Ended
	Jan. 26, 2024 USD ($) shares	Sep. 09, 2023 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) yr shares	Jun. 30, 2024 USD ($) yr shares
Autonomix Medical, Inc [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner	4.99%
Bridge Financing Warrants in Connection with Convertible Notes [Member[
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares		0.25
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1
Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)		180 days
Class of Warrant or Right, Percentage of Outstanding Stock		25%
Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input			1.0188	1.0188
Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr			5	5
Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0.044	0.044
Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input			0.20	0.20
Bridge Financing Warrants in Connection with Convertible Notes [Member[ | Measurement Input, Discount for Lack of Marketability [Member]
Warrants and Rights Outstanding, Measurement Input			0.1577	0.1577
Conversion of Convertible Notes to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares	335,000		335,000
Maximum [Member] | Autonomix Medical, Inc [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner	4.99%
The Notes [Member]
Proceeds from Convertible Debt				$ 2
Debt Instrument, Interest Rate, Effective Percentage			15.30%	15.30%
The Notes [Member] | Autonomix Medical, Inc [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner		4.99%
The Notes [Member] | Conversion of Convertible Notes to Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 2
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				1,000,000
The Notes [Member] | Maximum [Member]
Debt Instrument, Face Amount		$ 2
The Notes [Member] | Minimum [Member]
Interest Expense, Debt			$ 0.1
Convertible Debt with 4.99% Beneficial Ownership Limitation [Member]
Convertible Notes Payable	$ 1.3
Debt Instrument, Convertible, Number of Equity Instruments	665,000

Note 2 - Convertible Notes Pa_4

Note 2 - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024
Net carrying amount	$ 1,043	$ 1,002
The Notes [Member] | Convertible Debt [Member]
Zero-coupon convertible notes payable due on December 31, 2025	1,330
Amortized debt discount	287
Net carrying amount	$ 1,043

Note 2 - Convertible Notes Pa_5

Note 2 - Convertible Notes Payable - Schedule of Detachable Warrants (Details) - USD ($)		3 Months Ended	12 Months Ended
		Jun. 30, 2024	Mar. 31, 2024
Balance, outstanding (in shares)		500,000
Outstanding, weighted average exercise price (in dollars per share)		$ 1
Outstanding, remaining term (Year)		4 years 2 months 23 days	4 years 5 months 23 days
Outstanding, intrinsic value	[1]	$ 0	$ 1,010,000
Granted, outstanding (in shares)		0
Granted, weighted average exercise price (in dollars per share)		$ 0
Exercised, outstanding (in shares)		0
Exercised, weighted average exercise price (in dollars per share)		$ 0
Forfeited/Cancelled, outstanding (in shares)		0
Forfeited/Cancelled, weighted average exercise price (in dollars per share)		$ 0
Expired, outstanding (in shares)		0
Expired, weighted average exercise price (in dollars per share)		$ 0
Balance, outstanding (in shares)		500,000	500,000
Outstanding, weighted average exercise price (in dollars per share)		$ 1	$ 1
Exercisable (in shares)		500,000
Exercisable, weighted average exercise price (in dollars per share)		$ 1
Exercisable, remaining term (Year)		4 years 2 months 23 days
Exercisable, intrinsic value	[1]	$ 0
[1]Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. No outstanding and exercisable warrants issued in connection with the Company's Notes were in-the-money as of June 30, 2024.

Note 3 - Equity (Details Textua

Note 3 - Equity (Details Textual)					1 Months Ended	3 Months Ended
		May 13, 2024 shares	Apr. 01, 2024 shares	Jan. 26, 2024 USD ($) $ / shares shares	Aug. 31, 2023	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) shares	Mar. 31, 2024 USD ($) $ / shares shares	Feb. 15, 2024 USD ($) $ / shares shares	Nov. 29, 2023 $ / shares shares	Apr. 06, 2023 $ / shares shares
Stock Issued During Period, Value, New Issues | $							$ 2,840,000
Proceeds from Issuance of Common Stock | $						$ 0	2,840,000
Common Stock, Shares, Outstanding (in shares)						19,242,081		18,846,094
Common Stock, Shares Authorized (in shares)						500,000,000		500,000,000		500,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.001		$ 0.001		$ 0.001
Preferred Stock, Shares Authorized (in shares)						10,000,000		10,000,000		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.001		$ 0.001		$ 0.001
Common Stock, Shares, Issued (in shares)						19,242,081		18,846,094
Common Stock, Value, Issued | $						$ 19,000		$ 19,000
Payments of Stock Issuance Costs | $						$ 0	105,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease) (in shares)			942,305
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)						4,329,579		2,003,600
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						2,325,979
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares						$ 1.38
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $						$ 5,400,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)						5,344,569		5,744,569
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)	[1]					321,317
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number Outstanding, Number (in shares)						5,341,236
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense | $						$ 300,000	$ 0
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense | $						$ 100,000
The 2023 Stock Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)							4,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum					5%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)						0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)						2,325,979
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ / shares						$ 1.38
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number (in shares)						0
Restricted Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares									$ 3.8
Common Stock, Shares, Issued (in shares)									35,000
Common Stock, Value, Issued | $									$ 133,000
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount | $						$ 83,125
Restricted Stock [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense | $						$ 33,250	$ 0
Share-Based Payment Arrangement, Option [Member] | Black-Scholes Model [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share) | $ / shares						$ 2,600,000
Share-Based Payment Arrangement, Option [Member] | The 2023 Stock Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)						4 years
Warrant [Member]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $						$ 100,000
Share-Based Payment Arrangement, Expense | $						$ 100,000	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)						5,257,929
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercisable, Number Outstanding, Number (in shares)						5,257,929
Convertible Debt with 4.99% Beneficial Ownership Limitation [Member]
Convertible Notes Payable | $				$ 1,300,000
Debt Instrument, Convertible, Number of Equity Instruments				665,000
Maximum [Member] | Share-Based Payment Arrangement, Option [Member] | Black-Scholes Model [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate						4.39%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)						6 years 3 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate						130%
Minimum [Member] | Share-Based Payment Arrangement, Option [Member] | Black-Scholes Model [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount Rate						4.25%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate						110%
Autonomix Medical, Inc [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner				4.99%
Autonomix Medical, Inc [Member] | Maximum [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner				4.99%
Conversion of Convertible Notes to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)				335,000		335,000
IPO [Member]
Stock Issued During Period, Shares, New Issues (in shares)				2,234,222
Shares Issued, Price Per Share (in dollars per share) | $ / shares				$ 5
Stock Issued During Period, Value, New Issues | $				$ 11.2
Proceeds from Issuance of Common Stock | $				$ 9.8
Common Stock, Shares, Outstanding (in shares)				18,687,061
Stock Refunded During Period, Shares, IPO Common Stock (in shares)		1,050
Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						1,420,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares											$ 2
Stock Issued During Period, Value, New Issues | $						$ 2,840,000
Common Stock, Shares Authorized (in shares)											2,000,000
Payments of Stock Issuance Costs | $						$ 0
[1]Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock. No outstanding or exercisable options were in-the-money as of March 31, 2024.

Note 3 - Equity - General and A

Note 3 - Equity - General and Administrative Expense (Details) - General and Administrative Expense [Member] - USD ($)	3 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expense	$ 300,000	$ 0
Restricted Stock [Member]
Share-Based Payment Arrangement, Expense	$ 33,250	$ 0

Note 3 - Equity - Restricted St

Note 3 - Equity - Restricted Stock Activity (Details)	3 Months Ended
	Jun. 30, 2024 $ / shares shares
Balance, unvested restricted stock units, shares (in shares) | shares	23,333
Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares	$ 3.8
Restricted Stock [Member]
Balance, unvested restricted stock units, shares (in shares) | shares	32,083
Balance, unvested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares	$ 3.8
Granted, unvested restricted stock units, shares (in shares) | shares	0
Granted, unvested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0
Vested restricted stock units, shares (in shares) | shares	(8,750)
Vested restricted stock units, weighted average grant date fair value (in dollars per share) | $ / shares	$ 3.8

Note 3 - Equity - Schedule of S

Note 3 - Equity - Schedule of Stock Option Activity (Details) - USD ($)		3 Months Ended	12 Months Ended
		Jun. 30, 2024	Mar. 31, 2024
Outstanding, options (in shares)		2,003,600
Outstanding, options, weighted average exercise price (in dollars per share)		$ 2.33
Outstanding, options, Weighted average remaining contractual term (Year)		9 years 6 months 25 days	9 years 4 months 6 days
Outstanding and exercisable, March 31, 2024		$ 0	$ 1,680,672
Granted, options (in shares)		2,325,979
Granted, options, weighted average exercise price (in dollars per share)		$ 1.38
Exercised, options (in shares)		0
Exercised, options, weighted average exercise price (in dollars per share)		$ 0
Forfeited/Cancelled, options (in shares)		0
Forfeited/Cancelled, options, weighted average exercise price (in dollars per share)		$ 0
Expired, options (in shares)		0
Expired, options, weighted average exercise price (in dollars per share)		$ 0
Outstanding, options (in shares)		4,329,579	2,003,600
Outstanding, options, weighted average exercise price (in dollars per share)		$ 1.82	$ 2.33
Exercisable, options (in shares)	[1]	321,317
Exercisable, options, weighted average exercise price (in dollars per share)	[1]	$ 2
Exercisable, options, Weighted average remaining contractual term (Year)		8 years 8 months 8 days
Exercisable, June 30, 2024*		$ 0
[1]Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money stock. No outstanding or exercisable options were in-the-money as of March 31, 2024.

Note 3 - Equity - Schedule of E

Note 3 - Equity - Schedule of Equity-Based Stock Warrants (Details) - USD ($)		3 Months Ended	12 Months Ended
		Jun. 30, 2024	Mar. 31, 2024
Outstanding, warrants (in shares)		5,744,569
Outstanding, warrants, weighted average exercise price (in dollars per share)		$ 0.08
Outstanding, warrants, weighted average remaining contractual term (Year)		4 years 6 months 14 days	4 years 9 months 18 days
Outstanding, warrants, aggregate intrinsic value	[1]	$ 5,009,401	$ 17,072,147
Granted, warrants (in shares)		0
Granted, warrants, weighted average exercise price (in dollars per share)		$ 0
Exercised, warrants (in shares)	[2]	(397,037)
Exercised, warrants, weighted average exercise price (in dollars per share)	[2]	$ 0.01
Forfeited/Cancelled, warrants (in shares)		(2,963)
Forfeited/Cancelled, warrants, weighted average exercise price (in dollars per share)		$ 0.01
Expired, warrants (in shares)		0
Expired, warrants, weighted average exercise price (in dollars per share)		$ 0
Outstanding, warrants (in shares)		5,344,569	5,744,569
Outstanding, warrants, weighted average exercise price (in dollars per share)		$ 0.09	$ 0.08
Exercisable, warrants (in shares)		5,341,236
Exercisable, warrants, weighted average exercise price (in dollars per share)		$ 0.09
Exercisable, warrants, weighted average remaining contractual term ( (Year)		4 years 6 months 14 days
Exercisable, warrants, aggregate intrinsic value	[1]	$ 5,009,401
[1]Aggregate Intrinsic Value = Excess of market value over the exercise price of all in-the-money warrants. 5,257,929 outstanding and exercisable warrants were in-the-money as of June 30, 2024.[2]All exercised shares utilized the “cashless exercise” option.

Note 4 - Commitments and Cont_2

Note 4 - Commitments and Contingencies (Details Textual)		3 Months Ended
	Jun. 17, 2024 USD ($) shares	Jun. 30, 2024 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		2,325,979
Employment Contracts [Member]
Employee Benefits and Share-Based Compensation | $		$ 1,100,000
Employment Contracts [Member] | Chief Executive Officer [Member]
Employment Agreement, Term of Contract (Year)	3 years
Annual Base Salary | $	$ 450,000
Employment Agreement, Bonus as a Percentage of Annual Base Compensation	60%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value | $	$ 1,000,000
Employment Contracts [Member] | Chief Executive Officer [Member] | Scenario, Contract Termination [Member]
Employment Agreement, Bonus as a Percentage of Annual Base Compensation	100%
Employment Contracts [Member] | Chief Executive Officer [Member] | Scenario, Contract Termination, Without Cause [Member]
Employment Agreement, Bonus as a Percentage of Annual Base Compensation	50%
Employment Contracts [Member] | Chief Executive Officer [Member] | Inducement Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	900,000
Employment Contracts [Member] | Chief Executive Officer [Member] | Inducement Options [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	225,000
Employment Contracts [Member] | Chief Executive Officer [Member] | Inducement Options [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	225,000
Employment Contracts [Member] | Chief Executive Officer [Member] | Inducement Options [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	225,000
Employment Contracts [Member] | Chief Executive Officer [Member] | Inducement Options [Member] | Share-Based Payment Arrangement, Tranche Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	225,000
Employment Contracts [Member] | Executive Vice Chair and Strategic Advisor to the Chief Executive Officer [Member]
Employment Agreement, Term of Contract (Year)	2 years
Annual Base Salary | $	$ 150,000
Employment Agreement, Bonus as a Percentage of Annual Base Compensation	50%
Pending Litigation [Member]
Loss Contingency, Pending Claims, Number		0

Note 5 - Related Party Transa_2

Note 5 - Related Party Transactions (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended
	Jan. 29, 2024	Jul. 07, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024
The Warrant [Member] | Termination Agreement [Member]
Class of Warrant or Right, Value of Securities Called by Warrants or Rights	$ 8,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.001	$ 0.001
Warrants and Rights Outstanding, Term (Year)	5 years	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,600,000
The Warrant [Member] | Termination Agreement [Member] | Common Stock, 6 Months Lock-up Period [Member]
Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)		6 months
Class of Warrant or Right, Percentage of Outstanding Stock	12.50%	12.50%
The Warrant [Member] | Termination Agreement [Member] | Common Stock, 12 Months Lock-up Period [Member]
Class of Warrant or Right, Lock-up Agreement Term of Underlying Shares (Day)		12 months
Management, Board of Director, and Family [Member]
Related Party Transaction, Amounts of Transaction			$ 500
Management, Board of Director, and Family [Member] | The Bridge Offering [Member]
Proceeds from Issuance of Debt			0	$ 100
Accounting and Financial Reporting Services [Member] | Chief Financial Officer [Member]
Accounts Payable and Accrued Liabilities			0
Accounting and Financial Reporting Services [Member] | Chief Financial Officer [Member] | Maximum [Member]
Accounts Payable and Accrued Liabilities					$ 100
Management [Member]
Related Party Transaction, Amounts of Transaction			400
Related Party [Member]
Related Party Transaction, Amounts of Transaction			$ 100

Note 6 - Subsequent Events (Det

Note 6 - Subsequent Events (Details Textual) - RF Innovations, Inc. [Member] - Subsequent Event [Member] - $ / shares		1 Months Ended
	Jul. 10, 2024	Jul. 30, 2024
Stock Issued During Period, Shares, New Issues (in shares)	250,000
Stock Issued During Period, Shares, Warrants Exercised (in shares)		3,594,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		3,544,852
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.01